Speakers
Jennifer Doudna, Matt Jacobson, Herbert “Skip” Virgin, Carol Suh, Hal Barron, Catherine Lucey, George Scangos, Vineeta Agarwala, Nevan Krogan, Ron Leuty
Host
QBI
QBI is hosting an event with expert, renowned speakers who will contribute to candid discussions between academia, industry and venture capitalists on “Optimizing the Transition from Science to Drugs.” The event includes a line up of academic thought leaders, industry veterans, leading venture capitalists, and biotech media who will discuss how these key contributors can work more efficiently to turn scientific innovations into breakthrough therapies.
AGENDA
10:00 AM – Opening remarks
10:20 AM – Panel 1: Current State of Affairs of Academia/VC Relationships
Jennifer Doudna, PhD – Professor, UC Berkeley
Matt Jacobson, PhD – Professor, UC San Francisco
Herbert “Skip” Virgin, MD, PhD – Professor, Washington University
Moderated by Carol Suh – Partner, ARCH Venture Partners
11:00 AM – Break
11:30 AM – Panel 2: Altos Labs: A Different Approach
Hal Barron, MD – CEO, Altos Labs
Catherine Lucey, MD – Executive Vice Chancellor & Provost, UC San Francisco
Moderated by George Scangos, PhD – Biotech Veteran
12:10 PM – Panel 3: How Do We Optimize Academia/Industry Relationships?
Vineeta Agarwala, MD, PhD – General Partner, a16z
Nevan Krogan, PhD – Director, QBI
George Scangos, PhD – Biotech Veteran
Moderated by Ron Leuty – Senior Reporter, SF Business Times
12:50 PM – Lunch Reception
Jennifer Doudna, PhD – Professor, UC Berkeley
Matt Jacobson, PhD – Professor, UC San Francisco
Herbert “Skip” Virgin, MD, PhD – Professor, Washington University
Moderated by Carol Suh – Partner, ARCH Venture Partners
Hal Barron, MD – CEO, Altos Labs
Catherine Lucey, MD – Executive Vice Chancellor & Provost, UC San Francisco
Moderated by George Scangos, PhD – Biotech Veteran
Vineeta Agarwala, MD, PhD – General Partner, a16z
Nevan Krogan, PhD – Director, QBI
George Scangos, PhD – Biotech Veteran
Moderated by Ron Leuty – Senior Reporter, SF Business Times
12:50 PM – Lunch Reception